These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 111085)

  • 1. [Treatment of alcoholic toxic fatty liver. A placebo-controlled trial with hepavis (author's transl)].
    Deynet G; Reimer F
    MMW Munch Med Wochenschr; 1979 Jun; 121(24):831-2. PubMed ID: 111085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Does Hepavis have value in the therapy of fatty liver caused by alcohol poisoning?].
    Odegaard S; Busch D
    Z Gastroenterol; 1989 Feb; 27(2):91-3. PubMed ID: 2658394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Reflections on medicamentous liver-therapy. Hepavis in medical practice].
    Wegener W
    Med Monatsschr; 1977 Jul; 31(7):328-30. PubMed ID: 904570
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical experience report on Hepavis].
    Menninger U; Menninger W
    Med Welt; 1980 Oct; 31(42):1519-21. PubMed ID: 7453534
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical experience with the oral liver-therapeutic agent Hepavis].
    Bayazid A; Gerhard W
    Med Welt; 1976 Nov; 27(46):2248-9. PubMed ID: 794616
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment with Hepavis, a new cholerectically-active hepaticum. Experiences from an internal medicine profemoral practice].
    Stuchlik S
    Med Monatsschr; 1977 Nov; 31(11):524-6. PubMed ID: 927326
    [No Abstract]   [Full Text] [Related]  

  • 7. [Repair, regeneration and metabolism of liver cells: a clinical report].
    Blasy J
    ZFA (Stuttgart); 1979 Apr; 55(12):787-91. PubMed ID: 375610
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease.
    Orrego H; Kalant H; Israel Y; Blake J; Medline A; Rankin JG; Armstrong A; Kapur B
    Gastroenterology; 1979 Jan; 76(1):105-15. PubMed ID: 758131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Controlled clinical trial of a new combination of phosphorylcholine, homocysteine-gamma-thiolactone and vitamin B 12 in the parenteral treatment of chronic hepatopathies].
    Bandini S; Monteforte S
    Clin Ter; 1974 Jun; 69(6):549-60. PubMed ID: 4845637
    [No Abstract]   [Full Text] [Related]  

  • 10. [Active therapeutic exercises in combination with vasoactive drug in intermittent claudication (author's transl)].
    Krause D; Dittmar K
    MMW Munch Med Wochenschr; 1978 Jan; 120(2-3):69-72. PubMed ID: 414129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic progress in chronic liver diseases].
    Wildhirt E
    Dtsch Z Verdau Stoffwechselkr; 1968; 28(2):207-8. PubMed ID: 4894834
    [No Abstract]   [Full Text] [Related]  

  • 12. [Tolerance of nitrefazole in alcoholics with liver disease. A 4-week placebo-controlled double-blind study].
    Feuerlein W; Heesch D; Schmidt L; Werner HP; Bethge H; Görtelmeyer R
    Fortschr Med; 1984 Apr; 102(14):409-13. PubMed ID: 6144620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alcoholic liver diseases and their treatment].
    Cacciatore L; Antoniello S; Russo M
    Clin Ter; 1989 Nov; 131(4):225-32. PubMed ID: 2480864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Observations on the treatment of chronic inflammatory liver diseases with the preparation Hepasteril B comp].
    Busse K; Otremba P
    Soins; 1970; 15(7):2608-13. PubMed ID: 4918343
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of alcoholic liver diseases. Abstinence, nutritional support, drug therapy, liver transplantation].
    Pár A
    Orv Hetil; 2000 Apr; 141(16):827-33. PubMed ID: 10817009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of chronic diseases of the liver with catergen].
    Loginov AS; Dzhalalov KD; Blok IuE; Bendikov EA; Ausheva LKh
    Ter Arkh; 1986; 58(2):73-6. PubMed ID: 3704945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glutathione in the treatment of chronic fatty liver diseases].
    Dentico P; Volpe A; Buongiorno R; Grattagliano I; Altomare E; Tantimonaco G; Scotto G; Sacco R; Schiraldi O
    Recenti Prog Med; 1995; 86(7-8):290-3. PubMed ID: 7569285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin.
    Hock B; Schwarz M; Domke I; Grunert VP; Wuertemberger M; Schiemann U; Horster S; Limmer C; Stecker G; Soyka M
    Addiction; 2005 Oct; 100(10):1477-86. PubMed ID: 16185209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of cirrhosis of the liver by a combination of Lipovitan and orotic acid (author's transl)].
    Fassati P; Spízek J; Fassati M
    Cas Lek Cesk; 1980 Jul; 119(27-28):770-3. PubMed ID: 7428000
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibitory effect of osthole on alcohol-induced fatty liver in mice.
    Sun F; Xie ML; Zhu LJ; Xue J; Gu ZL
    Dig Liver Dis; 2009 Feb; 41(2):127-33. PubMed ID: 18339590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.